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IDH mutational status is required for proper diagnosis according to the WHO criteria revised in 2016. The 
single nucleotide polymorphism (SNP) rs11554137 (IDH1105GGT) at codon 105 of IDH1 has been reported 
in patients with several tumor types, including those with glioma. The aim of this study is to investigate 
the prevalence of IDH1105GGT in a cohort of brain tumors, and its association with clinicopathologic 
features and IDH1 and IDH2 missense mutations. Exon 4 of IDH1 and IDH2 was analyzed in a series of 
brain tumors classified according to current WHO criteria. DNA from control individuals was analyzed 
to infer the prevalence of IDH1105GGT in the reference population. Analysis was performed using next 
generation sequencing. IDH1105GGT was three times more frequent in patients with tumors (44/293 
cases, 15.0%) vs. population controls (6/109, 5.5%) (p = 0.0102). IDH1105GGT was more frequent in grade 
III tumors (26.1%) compared to grade II (10.9%, p = 0.038) and grade IV tumors (13.7%, p = 0.041). 
IDH1105GGT was more frequent in grade II and III tumors without an IDH tumor missense mutation 
(43.8%) than in those with (11.5%, p = 0.005). The IDH1105GGT SNP likely represents an important genetic 
marker, worthy of additional investigation to better understand the clinical and biological features of 
IDH-WT infiltrating gliomas.
The isocitrate dehydrogenase (IDH) family includes three isozymes (IDH1, IDH2, IDH3) involved in the Krebs 
cycle as active participants in NADPH production. These proteins also play an important role in the cellular 
control of oxidative damage1,2. The IDH1 protein is localized to the cytoplasm and peroxisome, while IDH2 and 
IDH3 are located in mitochondria3. IDH1 mutations were first implicated in carcinogenesis by a high-throughput 
study of the mutational landscape of breast and colorectal cancers4. Since then, mutations in IDH1 or IDH2 
genes have been detected in many different tumors, primarily gliomas (>80% of grade II and grade III gliomas)5, 
acute myeloid leukemia (AML, ~15% of cases)6,7 and chondrosarcomas (~50% of cases)8. IDH mutations have 
been reported, albeit with a lower prevalence, in thyroid carcinoma (5–15% of cases)9,10, cholangiocarcinoma 
(15–20% of cases)11, and other solid neoplasms12–15. Among brain tumors IDH mutations are identified in over 
80% of grade II and grade III gliomas (astrocytomas, oligodendrogliomas)16,17 and in about 5% of glioblastomas 
(GBM)16. According to the 2016 World Health Organization (WHO) classification of Central Nervous System 
tumors, establishing whether a brain tumor is IDH mutated or wild-type (WT) is a crucial requisite for the clas-
sification of gliomas18.
The large majority of IDH1 cancer-associated mutations affect codon 132, resulting in the amino acidic 
arginine(R)-to-histidine(H) substitution (p.R132H, c.395 G > A). Mutations other than p.R132H are found with 
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a lower frequency, such as p.R132C (c.394 C > T), p.R132S (c.394 C > A), p.R132G (c.394 C > G) or p.R132L 
(c.395 G > T)5,17,19–21. However, other mutations not involving codon 132 have also been detected5. IDH-R132 
mutations, as well as other IDH1 and IDH2 mutations (such as IDH1-G97D, IDH1-Y139D, IDH2-R172, 
IDH2-R140) have been shown to produce the 2-hydroxyglutarate (2HG) oncometabolite, while other rare 
mutations (e.g. IDH1-H133Q, IDH1-I130M, IDH1-G123R, IDH1-I99M, IDH1-V178I, IDH1-V71I) result in 
decreased IDH activity without a concomitant increase in 2HG production22.
Usually, synonymous single nucleotide polymorphisms (SNPs) do not change protein function, insofar as the 
amino acid sequence of the protein is not affected by the nucleotide change. Some silent SNPs, however, may lead 
to a protein defect, for example when they are localized in a splicing site23,24. In the case of the IDH1 gene, Wagner 
et al. (2010) found a silent SNP in a cohort of cytogenetically normal AML samples, that changes codon 105 of 
exon 4 from “GGC” (Gly) to “GGT” (Gly)25. The SNP (p.G105G, rs11554137:C > T -IDH1105GGT, minor allele fre-
quency 0.0569) has since been frequently reported in AML and is linked to an adverse prognosis26–28. It has also 
been reported in brain tumors in a study of patients with gliomas (grade II to IV) from France and Germany29 
and in a series of Bulgarian GBM patients30, as well as in thyroid tumors (both carcinomas and adenomas)9,10.
The role and biologic significance of the IDH1105GGT SNP in tumorigenesis is poorly understood, but it appears 
to be associated with increased IDH1 mRNA levels leading to altered NADPH production25,29.
The aim of the present study was to assess the prevalence of the IDH1105GGT SNP in a cohort of Italian patients 
with brain tumors classified according to 2016 WHO criteria, and investigate its association with clinicopatho-
logic features and IDH tumor missense mutations.
Results
NGS primers allowed a reliable analysis of the nucleotide sequence of codon 105 in all samples. Overall, 
IDH1105GGT was found in 44 of 293 (15.0%) enrolled tumors (Table 1) and in 6 of 109 (5.5%) control individuals 
(p = 0.0102) (Fig. 1A).
In all but two patients harboring IDH1105GGT, the SNP was detected in about 50% of alleles analyzed (range: 
45–53%), a frequency that is fully compatible with a heterozygous germline event. In the other two patients, 
IDH1105GGT was detected in 100% of the alleles analyzed, compatible with a homozygous germline condition.
IDH1105GGTand histological grade. Seven of 64 (10.9%) grade II cases (including 59 gliomas, 4 epend-
ymomas and 1 neurocytoma) harbored IDH1105GGT (Fig. 1B), all but one in the heterozygous state. In one case 
(oligodendroglioma, IDH1-mutated and 1p/19q co-deleted), the SNP was detected in 100% of the alleles ana-
lyzed, compatible with a homozygous condition (Table 1). Among grade II gliomas, 6 of 59 (10.1%) harbored 
IDH1105GGT.
Diagnosis N° of cases IDH1105GGT (%)
Grade II tumors 64 7 (10.9)
Astrocytomas 34 4 (11.8)
Diffuse astrocytoma, IDH-WT 6 2 (33.3)
Diffuse astrocytoma, IDH-mutant 25 1 (4)
Gemistocytic Astrocytoma, IDH-mutant 1 1 (100)
Pleomorphicxanthoastrocytoma, IDH-WT 2 0 (−)
Oligodendrogliomas 25 2 (8)
Oligodendroglioma, IDH-mutant and 1p/19q codeleted 25 2° (8)
Other Grade II brain tumors 5 1 (20)
Ependymoma 4 0 (−)
Neurocytoma 1 1 (100)
Grade III tumors 46 12 (26.1)
Anaplastic Astrocytomas 29 9 (31.0)
Anaplastic astrocytoma, IDH-WT 7 4 (57.1)
Anaplasticastrocytoma, IDH-mutant 21 4 (19)
Anaplastic Pleomorphic xanthoastrocytoma, IDH1-WT 1 1 (100)
AnaplasticOligodendrogliomas 15 2 (13.3)
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q codeleted 15 2 (13.3)
Other Grade III brain tumors 3 1 (33.3)
Anaplastic ependimoma 2 1 (50.0)
Grade IV 183 25 (13.7)
Glioblastoma, IDH-WT 179 24° (13.4)
Glioblastoma, IDH-mutant 4 1 (25.0)
Table 1. Histological classification of the tumor samples analyzed and distribution ofIDH1105GGT. All the 
oligodendrogliomas harboured a mutation in IDH1 or IDH2 genes and showed co-deletion of chromosome 
arms 1p/19q. WT: Wild Type; °IDH1105GGTwas in the homozygous state.
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Twelve of 46 (26.1%) grade III tumors (including 43 gliomas and 3 anaplastic ependymomas) harbored 
IDH1105GGT, all in the heterozygous condition (Fig. 1B). Among grade III gliomas, 11 of 43 (26.6%) harbored 
IDH1105GGT (Table 1).
As regards grade IV tumors, 25 of 183 (13.7%) GBM were positive for IDH1105GGT (Fig. 1B), all but one (a 
GBM-IDH WT) in the heterozygous state.
We found a statistically significant difference in the prevalence of IDH1105GGT between tumor grades, with the 
highest frequency among tumors belonging to grade III, compared to grades II and IV (p = 0.038 and p = 0.041 
respectively, Chi-squared test, Fig. 1B). Also among gliomas, IDH1105GGT is more frequent in grade III than in 
grade II or IV cases (p = 0.039 and p = 0.046, respectively). No statistically significant difference in prevalence 
was observed between grades II and IV, for both tumors and gliomas (p = 0.5765 and p = 0.6546, respectively, 
Chi-squared test).
IDH1105GGT and other IDH mutations. We observed an IDH1 or IDH2 mutation in 51 of 64 (79.7%) grade 
II tumors (all 51 cases were gliomas and 37 of these harbored the common p.R132H IDH1 mutation), in 36 of 46 
(78.3%) grade III tumors (all 36 cases were gliomas and 31 harbored p.R132H), and in 4 of 183 (2.2%) grade IV 
tumors (all p.R132H).
Among 91 IDH-mutated gliomas, 11 (12.1%) also carried IDH1105GGT. In 31 gliomas, IDH1105GGT was detected 
in the absence of any IDH missense mutation. In accordance with data previously reported29, we found no corre-
lation between the presence of IDH missense mutations in the tumor and the presence of IDH1105GGT (p = 0.4749, 
Fisher’s exact test) (Fig. 1C). However, IDH1105GGT was more frequent in grade II and III gliomas without than 
with IDH missense tumor mutations (43.8% vs 11.5% respectively – p = 0.005, Fisher’s exact test) (Fig. 1D). The 
SNP was also more frequent in grade II and III gliomas lacking IDH missense mutations than in GBM lacking 
IDH missense mutations (43.8% vs. 13.4%, p = 0.005, Fisher’s exact test) (Fig. 1D).
IDH1105GGT and histological subtypes. In grade II and III tumors, IDH1105GGT was more frequent in astro-
cytomas (13 of 63 cases −20.6%) than in oligodendrogliomas (4 of 40 cases −10%), but the difference did not 
reach statistical significance (p = 0.1837, Fisher’s exact test). Even after the inclusion of GBMs in the astrocytoma 
group (38 of 246–15.4%), the prevalence of IDH1105GGT was not statistically different between the oligodendroglial 
and astrocytic lineages (p = 0.4743, Fisher’s exact test).
IDH1105GGT and age. The age of patients harboring IDH1105GGT ranged from 26 to 74 years (mean 51.7ys). 
These patients were slightly younger than those without the SNP (mean age 53.2ys; age range: 17–84ys), but the 
difference was not statistically significant (p = 0.4476, Mann Whitney test). Figure 2 summarizes the statisti-
cal relationship between age, IDH1105GGT and IDH missense tumor mutations. There are significant differences 
among patient age and the distribution of IDH1105GGT and that of IDH missense tumor mutations. In particular, 
patients bearing only the SNP (mean age 55.7 years) were older that patients bearing both the SNP and IDH mis-
sense tumor mutations (mean 45.6ys, p < 0.05, Tukey’s multiple comparisons test), or those bearing only missense 
mutations (mean 42.3ys, p < 0.001, Tukey’s multiple comparisons test).
Figure 1. Prevalence of IDH105GGT. (A) Comparison of IDH105GGT between controls and patients with brain 
tumors. (B) IDH105GGT in grade II, III and IV brain tumors. (C) IDH105GGTin gliomas with and without IDH 
tumor missense mutation. (D) IDH105GGT in grade II and III gliomas with and without IDH tumor missense 
mutation and in grade IV without IDH tumor missense mutation. IDH105GGT: cases with IDH105GGT; No-
IDH105GGT: cases without the IDH105GGT; GII: grade II brain tumors; GIII: grade III brain tumors; GIV: grade IV 
brain tumors; GBM: glioblastoma; R132: cases with IDH-missense mutation; WT: wild type.
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Discussion
In our Italian cohort, the prevalence of the IDH1105GGT SNP was considerably higher in patients with brain tumors 
compared to the control population (15.5% vs 5.5%, respectively).
Few studies have analyzed IDH1105GGT in brain tumors, likely because routine molecular pathology methods 
do not always allow its identification. IDH1105GGT status cannot be inferred by immunohistochemical methods, 
or by the mutation-specific PCR assays commonly used to diagnose p.R132H. Furthermore, sequencing requires 
the design of specific primers to include codon 105. Our NGS primers allowed us to reliably diagnose the SNP 
genotype in all samples.
Wang et al. in a cohort of French and German patients with gliomas, did not find a statistical correlation 
between IDH1105GGT and tumor histological grade29. In our cohort of Italian patients, we found a statistical associ-
ation of IDH1105GGT with grade III gliomas, in particular with grade III astrocytomas. Importantly, among grade II 
and III gliomas, IDH1105GGT was more frequent in those cases without IDH missense tumor mutations (Fig. 1D). 
Previous studies reported this polymorphism as an adverse prognostic factor in patients with acute myeloid 
leukemia25; findings in the series of Wang et al. suggested a strong association with adverse outcome in patients 
with malignant glioma29. No association of the IDH1105GGT SNP with survival was found in the GBM series of 
Stancheva et al.30.
Although the functional effects of this polymorphism are still unclear, prediction analysis has shown that 
nucleotide 315 of the IDH1 gene may be within a putative Exonic Splicing Silencer (ESS) motif (ESRsearch Tool, 
http://esrsearch.tau.ac.il/)31. A nucleotide substitution in this region could lead to a protein defect due to incorrect 
regulation of constitutive or alternative splicing. Moreover, IDH1105GGT may be in linkage disequilibrium with 
other “tumor predisposing” variants.
Current opinion favors the existence of two major glioma groups: IDH-mutant gliomas, that are typically 
grade II and III tumors with a relatively favorable prognosis and IDH-WT tumors with a worse prognosis. As 
the large majority of IDH-WT tumors are grade IV, some authors have suggested that IDH-WT astrocytomas are 
in fact under-sampled IDH-WT GBMs and that they should be treated accordingly32. However, some subsets of 
IDH-WT low-grade gliomas do not have the molecular characteristics of GBM. These tumors likely represent 
other entities on a biological level. Some IDH-WT astrocytomas correspond to so called “pediatric type” tumors, 
sharing genetic and epigenetic features with pilocytic astrocytomas33.
In this context, the IDH1105GGT SNP may represent an important marker to further dissect and understand the 
clinical and biological features of IDH-WT infiltrating gliomas. Additional studies are warranted to clearly define 
the genetic profile and clinical outcome of patients with the IDH1105GGT SNP.
Methods
Case selection. A total of 293 consecutive cases of primitive brain tumors (64 grade II tumors, 46 grade 
III tumors, 183 grade IV tumors) were retrieved from the archives of Anatomic Pathology of Bellaria Hospital 
(Bologna, Italy). Samples were diagnosed and reclassified according to 2016 WHO criteria18. Patients were 
181 males (61.8%) and 112 females (38.2%), aged from 17 to 84 years (mean age 52.9ys). Control DNA 
samples were analyzed from the peripheral blood of 109 individuals who underwent blood testing at the 
same institution to infer the prevalence of IDH1105GGT in the reference population. None of the controls 
was affected by brain tumor or other neoplastic diseases. The study was approved by Ethic Committee of 
Figure 2. Age distribution of patients according to the presence of IDH1105GGT and IDH missense tumor 
mutations. IDH1105GGT: patients with tumor with IDH1105GGT; IDH1105WT: patients with tumor without 
IDH1105GGT; IDHmut: patients with tumor with IDH missense mutation; IDHWT: patients with tumor without 
IDH missense mutation. *p < 0.05 (Tukey’s multiple comparisons test); ***p < 0.001 (Tukey’s multiple 
comparisons test). Bars represent standard deviation (SD).
www.nature.com/scientificreports/
5SCIENTIFIC REPORtS |  (2018) 8:4459  | DOI:10.1038/s41598-018-22222-y
Azienda Sanitaria Locale di Bologna (protocol number CE09113 of 29th September 2013, Bologna, Italy). 
All information regarding the human material was managed using anonymous numerical codes and all 
samples were handled in compliance with the Helsinki Declaration (https://www.wma.net/policies-post/
wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/).
IDH1 and IDH2 analysis. All analyses were performed on DNA from formalin fixed and paraffin embed-
ded (FFPE) specimens, extracted with the QuickExtract FFPE DNA Extraction Kit (Epicentre, Madison, WI, 
U.S.A.). Control DNA from blood specimens were extracted using the MasterPure DNA Purification Kit 
(Epincentre, Madison WI, USA). IDH1 (exon 4, codons 96–138) and IDH2 (exon 4, codons 151–178) ampli-
cons were generated using the following primers: IDH1 Fw 5′-GAAACAAATGTGGAAATCACCA-3′, IDH1 
Rv 5′-TCACATTATTGCCAACATGACT-3′; IDH2 Fw 5′-AGCCCATCATCTGCAAAAA-3′, IDH2 Rv 
5′-TGTGGCCTTGTACTGCAGA-3′. The IDH1105GGT SNP (rs11554137) is 27 codons (81 nucleotides) upstream 
of the IDH1 hot spot codon (p.R132), well within the DNA region amplified by our set of primers.
Sequencing was performed using the 454 GS-Junior next generation sequencer (NGS) (Roche Diagnostic, 
Mannheim, Germany) according to established protocols (http://www.454.com/)34.
Categorical variables were compared using the Chi-square test or Fisher’s exact test. Continuous variables 
were compared using the Mann-Whitney test. Statistical comparison among IDH1 alterations and age was deter-
mined by the one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. A p-value < 0.05 was 
considered as statistically significant. Statistical analyses were performed using GraphPad Prism 6.01 (GraphPad 
Software).
Data availability. The datasets analysed during the current study are available from the corresponding 
author on reasonable request.
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